Comorbidities, multimorbidity and COVID-19

CD Russell, NI Lone, JK Baillie - Nature medicine, 2023 - nature.com
The influence of comorbidities on COVID-19 outcomes has been recognized since the
earliest days of the pandemic. But establishing causality and determining underlying …

COVID-19 and diabetes mellitus: from pathophysiology to clinical management

S Lim, JH Bae, HS Kwon, MA Nauck - Nature Reviews Endocrinology, 2021 - nature.com
Initial studies found increased severity of coronavirus disease 2019 (COVID-19), caused by
infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in patients …

Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective …

AS Lauring, MW Tenforde, JD Chappell, M Gaglani… - bmj, 2022 - bmj.com
Objectives To characterize the clinical severity of covid-19 associated with the alpha, delta,
and omicron SARS-CoV-2 variants among adults admitted to hospital and to compare the …

Convalescent plasma for covid-19–induced ARDS in mechanically ventilated patients

B Misset, M Piagnerelli, E Hoste… - … England Journal of …, 2023 - Mass Medical Soc
Background Passive immunization with plasma collected from convalescent patients has
been regularly used to treat coronavirus disease 2019 (Covid-19). Minimal data are …

Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis

P Domingo, I Mur, GM Mateo, M del Mar Gutierrez… - Jama, 2021 - jamanetwork.com
Importance Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …

[HTML][HTML] Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization

M Taquet, Z Skorniewska, A Hampshire… - Nature medicine, 2023 - nature.com
Post-COVID cognitive deficits, including 'brain fog', are clinically complex, with both objective
and subjective components. They are common and debilitating, and can affect the ability to …

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK …

ASV Stuart, RH Shaw, X Liu, M Greenland, PK Aley… - The Lancet, 2022 - thelancet.com
Background Given the importance of flexible use of different COVID-19 vaccines within the
same schedule to facilitate rapid deployment, we studied mixed priming schedules …

Interleukin-6 receptor antagonists in critically ill patients with Covid-19–preliminary report

Remap-Cap Investigators, AC Gordon, PR Mouncey… - MedRxiv, 2021 - medrxiv.org
Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …

[HTML][HTML] Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South …

M Voysey, SAC Clemens, SA Madhi, LY Weckx… - The Lancet, 2021 - thelancet.com
Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control …

Early convalescent plasma for high-risk outpatients with Covid-19

FK Korley, V Durkalski-Mauldin… - … England Journal of …, 2021 - Mass Medical Soc
Background Early administration of convalescent plasma obtained from blood donors who
have recovered from coronavirus disease 2019 (Covid-19) may prevent disease …